The experience of four kidney transplantation programs from 1975 to 1986 was reviewed to determine the prevalence and clinical characteristics of perinephric abscess in renal transplant recipients. Seven cases were found, with a prevalence of 0.3% in 1,945 patients seen over a 12-year period in one program. Current prevalence appears markedly less than in older studies. Despite immunosuppression, signs and symptoms of perinephric abscess were prominent and included fever, flank and abdominal pain and tenderness, and abdominal mass. Perinephric abscesses were diagnosed 2 weeks to 52 months after transplantation and were associated with lymphoceles in two patients. Abdominal ultrasound and computed tomography were useful in diagnosis. Staphylococci (36%) and aerobic gram-negative rods (32%) were the most common pathogens in our seven patients combined with patients identified in a review of the English-language literature. Also of note were the presence of anaerobes (28%) and Candida albicans (4%). Therapy was successful in all of our seven patients.

Abscess↗

PubMedDate not supplied

Open trial of imipenem/cilastatin therapy for serious bacterial infections.

Imipenem is a new beta-lactam antibiotic with a wide spectrum of activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The efficacy and toxicity of this drug, when administered parenterally in combination with the dehydropeptidase I inhibitor cilastatin, were studied in 41 hospitalized patients with serious infections. Clinical cure was achieved in 26 (79%) of the 33 patients who could be evaluated and microbiologic cure in 23 (85%) of the 27 patients who could be evaluated. Adverse clinical or laboratory reactions were observed in seven (17%) of the 41 patients. Thus, imipenem/cilastatin was highly effective in the treatment of a wide variety of serious bacterial infections.

Adult↗

PubMedDate not supplied

Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy.

Lymphadenopathy is the most frequent clinical manifestation of acute acquired infection with Toxoplasma in the immunocompetent individual. One hundred seven cases of histologically verified toxoplasmic lymphadenitis were reviewed in an effort to determine the usual modes of clinical presentation and the incidence of extranodal disease. Toxoplasmic lymphadenitis most frequently involved a solitary lymph node in the head and neck regions, without systemic symptoms or extranodal disease and with a benign clinical course. However, serious extranodal disease did occur in some patients and included myocarditis, pneumonitis, encephalitis, chorioretinitis, and transmission of the infection to the fetus. Case histories are presented to illustrate important points with respect to clinical presentation, complications, and diagnosis.

Adult↗

PubMedDate not supplied

Role of serology in the diagnosis of toxoplasmic lymphadenopathy.

Serologic results obtained in 92 cases of toxoplasmic lymphadenopathy diagnosed by lymph node biopsy were reviewed, and guidelines for serologic diagnosis of this disease were established. When tests were first performed within six months of onset of lymphadenopathy, single high titers of IgG toxoplasma antibodies (suggestive of acute infection) were found with the Sabin-Feldman dye test and the direct agglutination test in 93% and 76% of cases, respectively. Observations of significant rises in titer were uncommon because of the late acquisition of sera. Within the first six months after the onset of lymphadenopathy, IgM toxoplasma antibody was demonstrable by the double-sandwich IgM enzyme-linked immunosorbent assay in 88% of cases and by the IgM-immunofluorescent antibody test in 78%. Twenty percent of patients who had serum samples drawn more than 12 months after onset lymphadenopathy still had IgM toxoplasma antibodies demonstrable by the enzyme-linked immunosorbent assay. No patient first tested six or more months after onset of lymphadenopathy was positive in the IgM-immunofluorescent antibody test. These results provide the basis for recommendations on the use of serologic tests for the diagnosis of acute toxoplasmic lymphadenopathy.

Adult↗

PubMedDate not supplied

Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.

The efficacy of cefonicid and of ceftriaxone, administered once daily for the treatment of lower respiratory tract bacterial infections (pneumonia or bronchitis), was evaluated and compared in 118 patients with chronic lung disease. The patients were randomly assigned to receive 1 gm of either drug, intravenously or intramuscularly, daily for three to 11 days (mean, seven days). Pathogenic bacteria were isolated from sputum in 59% of patients; Haemophilus influenzae and Streptococcus pneumoniae predominated. Clinical cure or improvement was noted in 95% and 93% of patients treated with cefonicid and ceftriaxone, respectively, and bacteriologic cure or improvement in 69% and 81% (the differences were not significant). Side effects were infrequent and similar in the two treatment groups, except that diarrhea was more common in the ceftriaxone group (11%, versus 4.4% in the cefonicid group). It is concluded that patients with chronic lung disease who experience acute exacerbations associated with infection caused by H influenzae or S pneumoniae, or other susceptible organisms, can be effectively treated with once-daily administration of either cefonicid or ceftriaxone.

Adult↗

PubMedDate not supplied

The enhancing effect of donor pretreatment and low dose immunosuppression in dogs.

Explore the source record for details and available documents.

Animals↗